Amarin Advances VASCEPA with Over 25 Million Global Prescriptions and New Therapy Insights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Source: Globenewswire
- Global Prescription Volume: Amarin's VASCEPA®/VAZKEPA® has surpassed 25 million prescriptions worldwide, demonstrating its broad acceptance and efficacy in cardiovascular treatment, thereby solidifying the company's market leadership.
- Therapeutic Innovation: The emergence of new therapies is expected to expand the use of existing treatment options, including VASCEPA, helping to meet the needs of tens of millions of cardiovascular disease patients globally, thus enhancing patient access and treatment outcomes.
- Clinical Evidence Support: According to the 2018 REDUCE-IT study, VASCEPA demonstrated a 25% reduction in cardiovascular events when used in conjunction with statin therapy, providing robust clinical support for its application in cardiovascular risk management.
- Market Expansion Plans: Amarin has signed a long-term exclusive licensing agreement with Recordati S.p.A. to commercialize VAZKEPA across 59 countries, further enhancing its influence in the European market and expected to drive future sales growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMRN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMRN
Wall Street analysts forecast AMRN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMRN is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
0 Buy
0 Hold
1 Sell
Moderate Sell
Current: 15.420
Low
10.00
Averages
10.00
High
10.00
Current: 15.420
Low
10.00
Averages
10.00
High
10.00
About AMRN
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Amarin Advances VASCEPA with Over 25 Million Global Prescriptions and New Therapy Insights
- Global Prescription Volume: Amarin's VASCEPA®/VAZKEPA® has surpassed 25 million prescriptions worldwide, demonstrating its broad acceptance and efficacy in cardiovascular treatment, thereby solidifying the company's market leadership.
- Therapeutic Innovation: The emergence of new therapies is expected to expand the use of existing treatment options, including VASCEPA, helping to meet the needs of tens of millions of cardiovascular disease patients globally, thus enhancing patient access and treatment outcomes.
- Clinical Evidence Support: According to the 2018 REDUCE-IT study, VASCEPA demonstrated a 25% reduction in cardiovascular events when used in conjunction with statin therapy, providing robust clinical support for its application in cardiovascular risk management.
- Market Expansion Plans: Amarin has signed a long-term exclusive licensing agreement with Recordati S.p.A. to commercialize VAZKEPA across 59 countries, further enhancing its influence in the European market and expected to drive future sales growth.
Continue Reading
Daily Upgrade Report for Validea Kenneth Fisher Strategy - December 9, 2025
Validea's Upgrade for AMRN: Validea's Price/Sales Investor model, based on Kenneth Fisher's strategy, upgraded Amarin Corporation PLC (AMRN) from 28% to 60% due to improved fundamentals and valuation, indicating growing interest in the stock.
Company Overview: Amarin Corporation is a pharmaceutical company focused on developing therapeutics for cardiovascular health, primarily through its lead product, Vascepa, which is used to reduce triglyceride levels in patients with severe hypertriglyceridemia.
Kenneth Fisher's Background: Kenneth Fisher, a prominent money manager and author, is known for popularizing the price/sales ratio as a stock evaluation tool and is the founder of Fisher Investments, located in a forest preserve to encourage independent thinking away from Wall Street.
Validea's Investment Research: Validea provides investment research based on the strategies of successful investors like Warren Buffett and Benjamin Graham, offering stock analysis and model portfolios aimed at long-term market outperformance.
Continue Reading